Addition of immunotherapy to chemotherapy improves progression-free survival in anal canal
The PODIUM-303 study shows practice-changing results for patients with unresectable locally recurrent or metastatic squamous cell carcinoma of the anal canal
KRAS and TP53 may have a key role in the development of pancreatic cancer
Studies provide new insights into the driver landscape of these gastrointestinal tumours and show improved prediction of patient-specific outcomes.
First-line immunotherapy combination improves overall survival in HER2-positive metastatic G/GEJ adenocarcinoma
Final analysis of the KEYNOTE-811 trial reports positive findings when adding pembrolizumab to trastuzumab and chemotherapy in treatment-naïve patients
Neoadjuvant chemoradiotherapy has no role in the treatment of operable gastric cancer
Final late-phase trial results show that the addition of pre-operative chemoradiotherapy to peri-operative chemotherapy does not improve long-term outcomes in patients
Cancer in old patients: geriatric assessment and management plays a crucial role to provide personalised care
First recommendations are released from the ESMO/SIOG Cancer in the Elderly Working Group
Doublet immunotherapy consolidates its role in hepatocellular carcinoma
Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced disease
Ten years of improvement in the treatment of liver cancer
Novel agents, a rethinking of accepted treatment concepts and new roles for older treatment modalities are now driving liver cancer management
Growing evidence supports the use of ctDNA as a biomarker in colon cancer
Data from clinical trials show the value of liquid biopsy in treatment decision-making and prognostication
Harnessing the power of the gut microbiome in colorectal cancer
Lessons learned about the importance of the gut microbiome composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care
Liver transplantation plus chemotherapy prolongs survival in patients with definitively unresectable colorectal liver metastases
In the TRANSMET trial, a 5-year overall survival benefit was observed in a highly selected patient population